APO Research
Talk to an analyst

APO RESEARCH · REPORT

OTC Anti-Infective Medications

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global OTC Anti-Infective Medications Market Outlook and Growth Opportunities 2026

2 January 2026191 pages

Choose your research edition.

Industry ResearchOTC Anti-Infective Medications Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal OTC Anti-Infective Medications Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal OTC Anti-Infective Medications Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal OTC Anti-Infective Medications Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal OTC Anti-Infective Medications Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global OTC Anti-Infective Medications market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for OTC Anti-Infective Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for OTC Anti-Infective Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for OTC Anti-Infective Medications is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the OTC Anti-Infective Medications market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the OTC Anti-Infective Medications market include Abbott, Sanofi, Novartis, Merck, Roche, Pfizer, GlaxoSmithKline, Optimer Pharmaceuticals and Novabay Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global OTC Anti-Infective Medications market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of OTC Anti-Infective Medications and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents OTC Anti-Infective Medications revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global OTC Anti-Infective Medications market.

OTC Anti-Infective Medications Segment by Company

Abbott

Sanofi

Novartis

Merck

Roche

Pfizer

GlaxoSmithKline

Optimer Pharmaceuticals

Novabay Pharmaceuticals

NanoViricides

MerLion Pharma

Bristol-Myers Squibb

Basilea Pharmaceutica

OTC Anti-Infective Medications Segment by Type

Antiseptic

Antiparasitics

Antifungals

OTC Anti-Infective Medications Segment by Application

E-Commerce

Drug Stores

Hospital Pharmacies

OTC Anti-Infective Medications Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global OTC Anti-Infective Medications status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the OTC Anti-Infective Medications key companies, revenue, market share, and recent developments.

3. To split the OTC Anti-Infective Medications breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions OTC Anti-Infective Medications market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify OTC Anti-Infective Medications significant trends, drivers, influence factors in global and regions.

6. To analyze OTC Anti-Infective Medications competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global OTC Anti-Infective Medications market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of OTC Anti-Infective Medications and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of OTC Anti-Infective Medications.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global OTC Anti-Infective Medications industry.

Chapter 3: Detailed analysis of OTC Anti-Infective Medications company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of OTC Anti-Infective Medications in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of OTC Anti-Infective Medications in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. OTC Anti-Infective Medications Industry Trends Table 2. OTC Anti-Infective Medications Industry Drivers Table 3. OTC Anti-Infective Medications Industry Opportunities and Challenges Table 4. OTC Anti-Infective Medications Industry Restraints Table 5. Global OTC Anti-Infective Medications Revenue by Company (US$ Million) & (2021-2026) Table 6. Global OTC Anti-Infective Medications Revenue Share by Company (2021-2026) Table 7. Global OTC Anti-Infective Medications Company Ranking, (2024-2026) & (US$ Million) Table 8. Global OTC Anti-Infective Medications Key Company Manufacturing Base & Headquarters Table 9. Global OTC Anti-Infective Medications Company, Product Type & Application Table 10. Global OTC Anti-Infective Medications Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global OTC Anti-Infective Medications by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Antiseptic Table 15. Significant Companies of Antiparasitics Table 16. Significant Companies of Antifungals Table 17. Global OTC Anti-Infective Medications Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global OTC Anti-Infective Medications Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global OTC Anti-Infective Medications Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global OTC Anti-Infective Medications Sales Value Share by Type (2021-2026) Table 21. Global OTC Anti-Infective Medications Sales Value Share by Type (2027-2032) Table 22. Significant Companies of E-Commerce Table 23. Significant Companies of Drug Stores Table 24. Significant Companies of Hospital Pharmacies Table 25. Global OTC Anti-Infective Medications Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global OTC Anti-Infective Medications Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global OTC Anti-Infective Medications Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global OTC Anti-Infective Medications Sales Value Share by Application (2021-2026) Table 29. Global OTC Anti-Infective Medications Sales Value Share by Application (2027-2032) Table 30. Global OTC Anti-Infective Medications Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global OTC Anti-Infective Medications Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global OTC Anti-Infective Medications Sales Value Share by Region (2021-2026) Table 33. Global OTC Anti-Infective Medications Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global OTC Anti-Infective Medications Sales Value Share by Region (2027-2032) Table 35. Global OTC Anti-Infective Medications Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global OTC Anti-Infective Medications Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global OTC Anti-Infective Medications Sales Value Market Share by Country (2021-2026) Table 38. Global OTC Anti-Infective Medications Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global OTC Anti-Infective Medications Sales Value Market Share by Country (2027-2032) Table 40. Abbott Company Information Table 41. Abbott Business Overview Table 42. Abbott OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Abbott OTC Anti-Infective Medications Product Portfolio Table 44. Abbott Recent Development Table 45. Sanofi Company Information Table 46. Sanofi Business Overview Table 47. Sanofi OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Sanofi OTC Anti-Infective Medications Product Portfolio Table 49. Sanofi Recent Development Table 50. Novartis Company Information Table 51. Novartis Business Overview Table 52. Novartis OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novartis OTC Anti-Infective Medications Product Portfolio Table 54. Novartis Recent Development Table 55. Merck Company Information Table 56. Merck Business Overview Table 57. Merck OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Merck OTC Anti-Infective Medications Product Portfolio Table 59. Merck Recent Development Table 60. Roche Company Information Table 61. Roche Business Overview Table 62. Roche OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Roche OTC Anti-Infective Medications Product Portfolio Table 64. Roche Recent Development Table 65. Pfizer Company Information Table 66. Pfizer Business Overview Table 67. Pfizer OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Pfizer OTC Anti-Infective Medications Product Portfolio Table 69. Pfizer Recent Development Table 70. GlaxoSmithKline Company Information Table 71. GlaxoSmithKline Business Overview Table 72. GlaxoSmithKline OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. GlaxoSmithKline OTC Anti-Infective Medications Product Portfolio Table 74. GlaxoSmithKline Recent Development Table 75. Optimer Pharmaceuticals Company Information Table 76. Optimer Pharmaceuticals Business Overview Table 77. Optimer Pharmaceuticals OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Optimer Pharmaceuticals OTC Anti-Infective Medications Product Portfolio Table 79. Optimer Pharmaceuticals Recent Development Table 80. Novabay Pharmaceuticals Company Information Table 81. Novabay Pharmaceuticals Business Overview Table 82. Novabay Pharmaceuticals OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Novabay Pharmaceuticals OTC Anti-Infective Medications Product Portfolio Table 84. Novabay Pharmaceuticals Recent Development Table 85. NanoViricides Company Information Table 86. NanoViricides Business Overview Table 87. NanoViricides OTC Anti-Infective Medications Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. NanoViricides OTC Anti-Infective Medications Product Portfolio Table 89. NanoViricides Recent Development Table 90. MerLion Pharma Company Information Table 91. MerLion Pharma Business Overview Table 92. MerLion Pharma OTC Anti-Infective Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. MerLion Pharma OTC Anti-Infective Medications Product Portfolio Table 94. MerLion Pharma Recent Development Table 95. Bristol-Myers Squibb Company Information Table 96. Bristol-Myers Squibb Business Overview Table 97. Bristol-Myers Squibb OTC Anti-Infective Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Bristol-Myers Squibb OTC Anti-Infective Medications Product Portfolio Table 99. Bristol-Myers Squibb Recent Development Table 100. Basilea Pharmaceutica Company Information Table 101. Basilea Pharmaceutica Business Overview Table 102. Basilea Pharmaceutica OTC Anti-Infective Medications Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. Basilea Pharmaceutica OTC Anti-Infective Medications Product Portfolio Table 104. Basilea Pharmaceutica Recent Development Table 105. Research Programs/Design for This Report Table 106. Authors List of This Report Table 107. Secondary Sources Table 108. Primary Sources List of Figures Figure 1. OTC Anti-Infective Medications Product Image Figure 2. Global OTC Anti-Infective Medications Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global OTC Anti-Infective Medications Market Size (2021-2032) & (US$ Million) Figure 4. Global OTC Anti-Infective Medications Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Antiseptic Image Figure 8. Antiparasitics Image Figure 9. Antifungals Image Figure 10. Global OTC Anti-Infective Medications Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global OTC Anti-Infective Medications Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global OTC Anti-Infective Medications Sales Value Share by Type (2021-2032) Figure 13. E-Commerce Image Figure 14. Drug Stores Image Figure 15. Hospital Pharmacies Image Figure 16. Global OTC Anti-Infective Medications Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global OTC Anti-Infective Medications Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global OTC Anti-Infective Medications Sales Value Share by Application (2021-2032) Figure 19. Global OTC Anti-Infective Medications Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global OTC Anti-Infective Medications Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America OTC Anti-Infective Medications Sales Value (2021-2032) & (US$ Million) Figure 22. North America OTC Anti-Infective Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe OTC Anti-Infective Medications Sales Value (2021-2032) & (US$ Million) Figure 24. Europe OTC Anti-Infective Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific OTC Anti-Infective Medications Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific OTC Anti-Infective Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America OTC Anti-Infective Medications Sales Value (2021-2032) & (US$ Million) Figure 28. South America OTC Anti-Infective Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa OTC Anti-Infective Medications Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa OTC Anti-Infective Medications Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Antiseptic
  • Antiparasitics
  • Antifungals
Applications
  • E-Commerce
  • Drug Stores
  • Hospital Pharmacies
Companies covered
  • Abbott
  • Sanofi
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Optimer Pharmaceuticals
  • Novabay Pharmaceuticals
  • NanoViricides
  • MerLion Pharma
  • Bristol-Myers Squibb
  • Basilea Pharmaceutica

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global OTC Anti-Infective Medications Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global OTC Anti-Infective Medications Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 OTC Anti-Infective Medications Market Dynamics
  1. 2.1 OTC Anti-Infective Medications Industry Trends
  2. 2.2 OTC Anti-Infective Medications Industry Drivers
  3. 2.3 OTC Anti-Infective Medications Industry Opportunities and Challenges
  4. 2.4 OTC Anti-Infective Medications Industry Restraints
3 OTC Anti-Infective Medications Market by Company
  1. 3.1 Global OTC Anti-Infective Medications Company Revenue Ranking in 2025
  2. 3.2 Global OTC Anti-Infective Medications Revenue by Company (2021-2026)
  3. 3.3 Global OTC Anti-Infective Medications Company Ranking (2024-2026)
  4. 3.4 Global OTC Anti-Infective Medications Company Manufacturing Base and Headquarters
  5. 3.5 Global OTC Anti-Infective Medications Company Product Type and Application
  6. 3.6 Global OTC Anti-Infective Medications Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global OTC Anti-Infective Medications Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 OTC Anti-Infective Medications Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 OTC Anti-Infective Medications Market by Type
  1. 4.1 OTC Anti-Infective Medications Type Introduction
  2. 4.1.1 Antiseptic
  3. 4.1.2 Antiparasitics
  4. 4.1.3 Antifungals
  5. 4.2 Global OTC Anti-Infective Medications Sales Value by Type
  6. 4.2.1 Global OTC Anti-Infective Medications Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global OTC Anti-Infective Medications Sales Value by Type (2021-2032)
  8. 4.2.3 Global OTC Anti-Infective Medications Sales Value Share by Type (2021-2032)
5 OTC Anti-Infective Medications Market by Application
  1. 5.1 OTC Anti-Infective Medications Application Introduction
  2. 5.1.1 E-Commerce
  3. 5.1.2 Drug Stores
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global OTC Anti-Infective Medications Sales Value by Application
  6. 5.2.1 Global OTC Anti-Infective Medications Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global OTC Anti-Infective Medications Sales Value by Application (2021-2032)
  8. 5.2.3 Global OTC Anti-Infective Medications Sales Value Share by Application (2021-2032)
6 OTC Anti-Infective Medications Regional Value Analysis
  1. 6.1 Global OTC Anti-Infective Medications Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global OTC Anti-Infective Medications Sales Value by Region (2021-2032)
  3. 6.2.1 Global OTC Anti-Infective Medications Sales Value by Region: 2021-2026
  4. 6.2.2 Global OTC Anti-Infective Medications Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America OTC Anti-Infective Medications Sales Value (2021-2032)
  7. 6.3.2 North America OTC Anti-Infective Medications Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe OTC Anti-Infective Medications Sales Value (2021-2032)
  10. 6.4.2 Europe OTC Anti-Infective Medications Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific OTC Anti-Infective Medications Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific OTC Anti-Infective Medications Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America OTC Anti-Infective Medications Sales Value (2021-2032)
  16. 6.6.2 South America OTC Anti-Infective Medications Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa OTC Anti-Infective Medications Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa OTC Anti-Infective Medications Sales Value Share by Country, 2025 VS 2032
7 OTC Anti-Infective Medications Country-level Value Analysis
  1. 7.1 Global OTC Anti-Infective Medications Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global OTC Anti-Infective Medications Sales Value by Country (2021-2032)
  3. 7.2.1 Global OTC Anti-Infective Medications Sales Value by Country (2021-2026)
  4. 7.2.2 Global OTC Anti-Infective Medications Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt OTC Anti-Infective Medications Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt OTC Anti-Infective Medications Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt OTC Anti-Infective Medications Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Abbott
  2. 8.1.1 Abbott Company Information
  3. 8.1.2 Abbott Business Overview
  4. 8.1.3 Abbott OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Abbott OTC Anti-Infective Medications Product Portfolio
  6. 8.1.5 Abbott Recent Developments
  7. 8.2 Sanofi
  8. 8.2.1 Sanofi Company Information
  9. 8.2.2 Sanofi Business Overview
  10. 8.2.3 Sanofi OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Sanofi OTC Anti-Infective Medications Product Portfolio
  12. 8.2.5 Sanofi Recent Developments
  13. 8.3 Novartis
  14. 8.3.1 Novartis Company Information
  15. 8.3.2 Novartis Business Overview
  16. 8.3.3 Novartis OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novartis OTC Anti-Infective Medications Product Portfolio
  18. 8.3.5 Novartis Recent Developments
  19. 8.4 Merck
  20. 8.4.1 Merck Company Information
  21. 8.4.2 Merck Business Overview
  22. 8.4.3 Merck OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck OTC Anti-Infective Medications Product Portfolio
  24. 8.4.5 Merck Recent Developments
  25. 8.5 Roche
  26. 8.5.1 Roche Company Information
  27. 8.5.2 Roche Business Overview
  28. 8.5.3 Roche OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Roche OTC Anti-Infective Medications Product Portfolio
  30. 8.5.5 Roche Recent Developments
  31. 8.6 Pfizer
  32. 8.6.1 Pfizer Company Information
  33. 8.6.2 Pfizer Business Overview
  34. 8.6.3 Pfizer OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pfizer OTC Anti-Infective Medications Product Portfolio
  36. 8.6.5 Pfizer Recent Developments
  37. 8.7 GlaxoSmithKline
  38. 8.7.1 GlaxoSmithKline Company Information
  39. 8.7.2 GlaxoSmithKline Business Overview
  40. 8.7.3 GlaxoSmithKline OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  41. 8.7.4 GlaxoSmithKline OTC Anti-Infective Medications Product Portfolio
  42. 8.7.5 GlaxoSmithKline Recent Developments
  43. 8.8 Optimer Pharmaceuticals
  44. 8.8.1 Optimer Pharmaceuticals Company Information
  45. 8.8.2 Optimer Pharmaceuticals Business Overview
  46. 8.8.3 Optimer Pharmaceuticals OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Optimer Pharmaceuticals OTC Anti-Infective Medications Product Portfolio
  48. 8.8.5 Optimer Pharmaceuticals Recent Developments
  49. 8.9 Novabay Pharmaceuticals
  50. 8.9.1 Novabay Pharmaceuticals Company Information
  51. 8.9.2 Novabay Pharmaceuticals Business Overview
  52. 8.9.3 Novabay Pharmaceuticals OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Novabay Pharmaceuticals OTC Anti-Infective Medications Product Portfolio
  54. 8.9.5 Novabay Pharmaceuticals Recent Developments
  55. 8.10 NanoViricides
  56. 8.10.1 NanoViricides Company Information
  57. 8.10.2 NanoViricides Business Overview
  58. 8.10.3 NanoViricides OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  59. 8.10.4 NanoViricides OTC Anti-Infective Medications Product Portfolio
  60. 8.10.5 NanoViricides Recent Developments
  61. 8.11 MerLion Pharma
  62. 8.11.1 MerLion Pharma Company Information
  63. 8.11.2 MerLion Pharma Business Overview
  64. 8.11.3 MerLion Pharma OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  65. 8.11.4 MerLion Pharma OTC Anti-Infective Medications Product Portfolio
  66. 8.11.5 MerLion Pharma Recent Developments
  67. 8.12 Bristol-Myers Squibb
  68. 8.12.1 Bristol-Myers Squibb Company Information
  69. 8.12.2 Bristol-Myers Squibb Business Overview
  70. 8.12.3 Bristol-Myers Squibb OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bristol-Myers Squibb OTC Anti-Infective Medications Product Portfolio
  72. 8.12.5 Bristol-Myers Squibb Recent Developments
  73. 8.13 Basilea Pharmaceutica
  74. 8.13.1 Basilea Pharmaceutica Company Information
  75. 8.13.2 Basilea Pharmaceutica Business Overview
  76. 8.13.3 Basilea Pharmaceutica OTC Anti-Infective Medications Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Basilea Pharmaceutica OTC Anti-Infective Medications Product Portfolio
  78. 8.13.5 Basilea Pharmaceutica Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst